No pain. All the gain.

NeoGenomics Reports Record Revenue of $66.1 Million on 16% Volume Growth and 13% Reduction in Average Cost per Test in the Second Quarter of 2017

New Article in Springer Nature

HER-2 Breast FISH Alternative Assessment

NeoGenomics Announces Expansion of Immuno-Oncology Profiling Tests

NeoGenomics Reports that its NeoLAB® Liquid Biopsy Prostate Test is More Accurate than Conventional Biopsies in Predicting High Grade Prostate Cancer

Combined Urine and Plasma Biomarkers are Highly Accurate for Predicting High Grade Prostate Cancer

Now Available: New Posters from AACR

NeoTYPE^® GI Predictive Profile

RAS/RAF, MSI, HER2, and PD-L1 to maximize options for therapy in GI cancers

Tumor Mutation Burden

Now available with NeoTYPE™ Solid Tumor Profiles and as stand-alone test

Learn more

All PD-L1 IHC IVD Assays Available

NeoGenomics leads the way in Immuno-Oncology with SP263 (NEW!), 28-8, 22C3, SP142

Learn more

The HPV RNA ISH Panel detects E6/E7 mRNA in 28 HPV subtypes. This test replaces the DNA ISH Panel effective February 27, 2017.

Learn more

HPV RNA ISH Panel

NeoLAB^TM EGFR T790M Liquid Biopsy

Learn more

Accurate and sensitive detection of the EGFR T790M mutation using cell-free plasma DNA

Universal Fusion/Expression Profile

Broad detection of fusion transcripts and gene expression in 1385 cancer genes

Learn more